Buscar
Organogenesis Holdings Inc
ORGOAñadir a la lista de seguimiento
2.370USD
-0.080-3.27%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
304.96MCap. mercado
PérdidaP/E TTM
Más Datos de Organogenesis Holdings Inc Compañía
Organogenesis Holdings Inc. is a regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. It offers a portfolio of regenerative products to address patient needs across the continuum of care. Its wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier, cross-linked with extracellular matrix scaffold for a variety of wound types; and Affinity, Novachor and NuShield placental allografts to address a variety of wound sizes and types as a protective barrier and extracellular matrix scaffold. Its sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM and PuraPly SX for the management of open wounds in a surgical setting.
Información de Organogenesis Holdings Inc
Símbolo de cotizaciónORGO
Nombre de la empresaOrganogenesis Holdings Inc
Fecha de salida a bolsaDec 02, 2016
Director ejecutivoGillheeney (Gary S)
Número de empleados869
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 02
Dirección85 Dan Rd
CiudadCANTON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02021-2810
Teléfono17815750775
Sitio Webhttps://investors.organogenesis.com
Símbolo de cotizaciónORGO
Fecha de salida a bolsaDec 02, 2016
Director ejecutivoGillheeney (Gary S)
Ejecutivos de Organogenesis Holdings Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Glenn H. Nussdorf
Mr. Glenn H. Nussdorf
Director
Director
12.25M
+4.08%
Mr. Patrick Bilbo
Mr. Patrick Bilbo
Chief Operating Officer
Chief Operating Officer
603.77K
-3.81%
Mrs. Lori Freedman, J.D.
Mrs. Lori Freedman, J.D.
Chief Administrative and Legal Officer
Chief Administrative and Legal Officer
552.73K
-7.99%
Mr. Brian Grow
Mr. Brian Grow
Chief Commercial Officer
Chief Commercial Officer
369.52K
-16.30%
Mr. Robert Cavorsi
Mr. Robert Cavorsi
Vice President - Strategy
Vice President - Strategy
275.52K
-0.25%
Mr. Arthur S. Leibowitz, CPA
Mr. Arthur S. Leibowitz, CPA
Lead Independent Director
Lead Independent Director
242.19K
+0.31%
Mr. Antonio S. Montecalvo
Mr. Antonio S. Montecalvo
Vice President - Health Policy
Vice President - Health Policy
217.76K
+13.57%
Ms. Prathyusha Duraibabu, CPA
Ms. Prathyusha Duraibabu, CPA
Independent Director
Independent Director
198.22K
+0.38%
Mr. Jon L. Giacomin
Mr. Jon L. Giacomin
Independent Director
Independent Director
192.20K
+0.39%
Dr. Gilberto Quintero, Ph.D.
Dr. Gilberto Quintero, Ph.D.
Independent Director
Independent Director
190.25K
+0.39%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Glenn H. Nussdorf
Mr. Glenn H. Nussdorf
Director
Director
12.25M
+4.08%
Mr. Patrick Bilbo
Mr. Patrick Bilbo
Chief Operating Officer
Chief Operating Officer
603.77K
-3.81%
Mrs. Lori Freedman, J.D.
Mrs. Lori Freedman, J.D.
Chief Administrative and Legal Officer
Chief Administrative and Legal Officer
552.73K
-7.99%
Mr. Brian Grow
Mr. Brian Grow
Chief Commercial Officer
Chief Commercial Officer
369.52K
-16.30%
Mr. Robert Cavorsi
Mr. Robert Cavorsi
Vice President - Strategy
Vice President - Strategy
275.52K
-0.25%
Mr. Arthur S. Leibowitz, CPA
Mr. Arthur S. Leibowitz, CPA
Lead Independent Director
Lead Independent Director
242.19K
+0.31%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Organogenesis Holdings Inc?
Los cinco principales accionistas de Organogenesis Holdings Inc son: Mr. Glenn H. Nussdorf
¿Cuántas instituciones poseen acciones de Organogenesis Holdings Inc (ORGO)?
A fecha de 2026Q1, 303 instituciones poseen acciones de Organogenesis Holdings Inc, con un valor de mercado combinado de aproximadamente 70.97M, lo que representa el 55.15% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -5515577.00.
¿Cuál es la mayor fuente de ganancias de Organogenesis Holdings Inc?
El 2026Q1, el segmento empresarial Advanced Wound Care generó la ganancia más alta para Organogenesis Holdings Inc, ascendiendo a 531.24M y representando el 94.35% de la ganancia total.